Strategies for assessing health economic and quality of life outcomes in multiple sclerosis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 6, 2002, Pages 577-587

  Duff, Steven B ^a   Mordin, Margaret M ^b  

^a Covance Hlth Econ/Out Serv Inc ^*  (United States)

^b Health Economics and Outcomes Research   (United States)

Author keywords

Cost effectiveness; Cost utility assessment; Drug therapy; Economic evaluation; Economic model; Health related quality of life; Multiple sclerosis; Utilities

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE CLASSIFICATION; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PREVALENCE; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW;

EID: 0036900762     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.6.577     Document Type: Review

References (57)

1. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RE Ransohoff RM. Management of multiple sclerosis. N. Engl. J. Med 337(22), 1604-1611 (1997).
2. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112(1), 133-146 (1989).
3. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 41(8), 1193-1196 (1991).
4. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can. J. Neurol. Sci. 20(1), 17-29 (1993).
5. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31(3), 333-336 (1992).
6. Williams R, Rigby AS, Airey M, Robinson M, Ford H. Multiple sclerosis: its epidemiological, genetic, and health care impact. J. Epidemiol. Community Health 49(6), 563-569 (1995).
7. Rosati G, Aiello I, Pirastru. MI et al. Epidemiology of multiple sclerosis in northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 15(1), 10-19 (1996).
8. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J. Neurol. Neurosurg. Psychiatry 58(5), 577-581 (1995).
9. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 40(5), 780-786 (1990).
10. Asche CV, Ho E, Chan B, Coyte PC. Economic consequences of multiple sclerosis for Canadians. Acta. Neurol. Scand. 95(5), 268-274 (1997).
11. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: cost of illness. Can. J. Neurol. Sci. 25(1),23-30 (1998).
12. Whetten-Goldstein K, Sloan EA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult. Scler. 4(5), 419-425 (1998).
13. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6(2), 91-98 (2000).
14. Kobelt G, Lindgren P, Parkin D et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. EFI Research Report 398. Stockholm School of Economics, Stockholm, Sweden (2000).
15. Kobelt G, Lindgren P, Smala A et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. Health Econ. Prev. Care 2(2), 60-68 (2001).
16. Amato MP, Battaglia MA, Caputo D et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol. 249(2), 152-163 (2002).
17. Blumhardt LD, Wood C. The economics of multiple sclerosis. Br. J. Med. Econ. 10(2), 99-118(1996)
18. Holmes BA, Madgwick T, Bates MA. The cost of multiple sclerosis. Br. J. Med. Econ. 8(4), 181-193 (1995).
19. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur. J. Neurol. 8(1), 27-35 (2001).
20. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 58(1), 37-43 (2002).
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (11), 1444-1452(1983).
22. Murphy N, Confavreux C, Haas J et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J. Neurol. Neurosurg. Psychiatry 65(4), 460-466 (1998).
23. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch. Neurol. 49(12), 1237-1242 (1992).
24. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: quality of life. Can. J. Neurol. Sci. 250(1), 31-38 (1998).
25. Fischer JS, Larocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult. Scler. 5(4), 251-259 (1999).
26. Ware JE, Snow KK, Kosinski M et al. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA, USA (1993).
27. Ritvo PG, Fischer JS, Miller DM, Andrew H, Pary DW, LaRocca NG. Multiple Sclerosis Quality of Life Inventory (MSQLI): A user's manual. National Multiple Sclerosis Society New York, NY, USA (1997).
28. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 4(3), 187-206 (1995).
29. Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J. Clin. Epidemiol. 50(5), 5 57-569 (1997).
30. Cella DF, Dineen K, Arnason B et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47(1), 129-139 (1996).
31. Rotstein Z, Barak Y, Noy S, Achiron A. Quality of life in multiple sclerosis: development and validation of the 'RAYS' Scale and comparison with die SF-36. Int. J. Qual. Health Care 12(6), 511-517 (2000).
32. Lankhorst GJ, Jelles F, Smits RCF et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J. Neurol. 243(6), 469-474 (1996).
33. Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA. Measurement of health-related quality of life in multiple sclerosis patients. Can. J. Neurol. Sci. 23(2), 99-103 (1996).
34. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurologv 53(5), 1098-1103 (1999).
35. Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68(2), 150-156 (2000).
36. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br. Med. J. 314(7094), 1580-1583 (1997).
37. Di Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys. Ther. 77(12), 1704-1716 (1997).
38. Rice GP, Oger J, Duquette P et al. Treatment with interferon beta- 1b improves quality of life in multiple sclerosis. Can. J. Neurol. Sci. 26(4), 276-282 (1999).
39. Schwartz CE, Vollmer T, Lee H, the North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 52(1), 63-70 (1999).
40. Pfennings L, Cohen L, Miller D et al. Using the short form-36 with multiple sclerosis patients in five countries: A cross-cultural comparison. Psychological Reports 85(1), 19-31 (1999).
41. Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev. Pharmacoeconomics Outcomes Res. 1(2), 215-228 (2001).
42. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatry 68 (2), 144-149 (2000).
43. Kobelt G, Jönsson L, Miltenburger C, Jönsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Healthcare 18(1), 127-138 (2002).
44. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med. Decis. Making 17(1), 1-9 (1997).
45. Shmueli A. The SF-36 profile and health-related quality of life: an interpretative analysis. Qual. Life Res. 7(3), 187-195 (1998).
46. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the Health Utility Index (HUI2) from the SF-36. Med. Decis. Making 21(2), 105-112 (2001).
47. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271-292 (2002).
48. The European Study Group on Interferon Beta-1 in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta- 1b in secondary progressive multiple sclerosis. Lancet 352(9139), 1491-1497 (1998).
49. Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jönsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int. J. Technol, Assess. Healthcare 16(3), 768-780 (2000).
50. Tappenden P, Chilcott J, O'Hagan T et al. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. Final report to the National Institute for Clinical Excellence. School of Health and Related Research, University of Sheffield, UK (2001).
51. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol. Assessment 2(4), iii-54 (1998).
52. Nunnally JC. Psychometric Theory McGraw-Hill, New York, NY, USA (1978).
53. Ware JE. Methodological considerations in the selection of health status assessment procedures. In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Wenger NK, Mattson ME, Furberg CD, Elinson J, (Eds) Le Jacq Inc., NY, USA (1984).
54. Brown MG, Murray TJ, Skerris IS et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. Int. J. Technol. Assess. Healthcare 16(3), 751-767 (2000).
55. Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon-β may be cost effective. PharmacoEconomics 18(1), 45-53 (2000).
56. Phillips CJ, Gilmour L, Gale R, Palmer M. A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. 4, 35-50 (2001).
57. Nuijten MJC, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 5(1), 44-54 (2002).